CTOs on the Move

RareMed

www.raremed.com

 
RareMed Solutions offers comprehensive support services for specialty, orphan and ultra-orphan products. Our team has a breadth of experience developing and maintaining therapy specific solutions to ensure compliance. RareMed Solutions is the ideal partner for biotech firms and pharmaceutical manufacturers due to our custom solutions that are unique to each of our partner’s needs. RareMed Solutions is committed to providing the highest level of care to patients we serve. We offer specialized, highly-customizable services designed to increase patient access, affordability, and adherence to therapy. The extensive experience and unmatched service delivery translates to the best possible care for ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.raremed.com
  • 305 Merchant Lane
    Pittsburgh, PA USA 15205
  • Phone: 833.676.7273

Executives

Name Title Contact Details
Dennis Whalen
 Vice President of Technology and Chief Technology Officer Profile

Similar Companies

Ostrove Associates

Ostrove Associates is a Elizabeth, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Talley Group

Talley Group | Specialists in pressure relieving mattresses and cushions, electric bed frames, negative pressure wound therapy, IPC, and infection control

West-Ward Pharmaceutical Corp

West-Ward Pharmaceutical Corp is a Eatontown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Brighton Pharmaceuticals

Brighton Pharmaceuticals is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ophthotech

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech`s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech`s second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.